Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2018

20.12.2017 | Focussed Research Review

Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints

verfasst von: Avishai Shemesh, Michael Brusilovsky, Kiran Kundu, Aner Ottolenghi, Kerry S. Campbell, Angel Porgador

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

The natural cytotoxicity receptors (NCRs; NKp30, NKp44, and NKp46) were first defined as activating receptors on human NK cells that are important in recognition of and response to tumors. A flurry of recent research, however, has revealed that differential splicing can occur during transcription of each of the NCR genes, resulting in some transcripts that encode receptor isoforms with inhibitory functions. These alternative transcripts can arise in certain tissue microenvironments and appear to be induced by cytokines. Evidence indicates that some of the inhibitory NCRs are triggered by specific ligands, such as the interaction of the inhibitory isoform of NKp44 with PCNA on the surface of tumor cells. Here, we review the different NCR splice variants, cytokines that modulate their expression, their functional impacts on innate immune cells, and their differential expression in the contexts of cancer, pregnancy, and infections. The recent discovery of these inhibitory NCR isoforms has revealed novel innate immune checkpoints, many of which still lack defined ligands and clear mechanisms driving their expression. These NCR checkpoint pathways offer exciting potential therapeutic targets to manipulate innate immune functions under defined pathological conditions, such as cancer, pregnancy disorders, and pathogen exposure.
Literatur
1.
Zurück zum Zitat Kruse PH, Matta J, Ugolini S, Vivier E (2014) Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 92(3):221–229CrossRef Kruse PH, Matta J, Ugolini S, Vivier E (2014) Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 92(3):221–229CrossRef
2.
Zurück zum Zitat Pessino A, Sivori S, Bottino C et al (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188(5):953–960CrossRef Pessino A, Sivori S, Bottino C et al (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188(5):953–960CrossRef
3.
Zurück zum Zitat Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22:405–429CrossRef Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22:405–429CrossRef
4.
Zurück zum Zitat Pende D, Parolini S, Pessino A et al (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190(10):1505–1516CrossRef Pende D, Parolini S, Pessino A et al (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190(10):1505–1516CrossRef
5.
Zurück zum Zitat Walzer T, Blery M, Chaix J et al (2007) Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 104(9):3384–3389CrossRef Walzer T, Blery M, Chaix J et al (2007) Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 104(9):3384–3389CrossRef
6.
Zurück zum Zitat Vitale M, Bottino C, Sivori S et al (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187(12):2065–2072CrossRef Vitale M, Bottino C, Sivori S et al (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187(12):2065–2072CrossRef
7.
Zurück zum Zitat Mattiola I, Pesant M, Tentorio PF et al (2015) Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1beta, IFN-beta, and IL-15 pathways. J Immunol 195(6):2818–2828CrossRef Mattiola I, Pesant M, Tentorio PF et al (2015) Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1beta, IFN-beta, and IL-15 pathways. J Immunol 195(6):2818–2828CrossRef
8.
Zurück zum Zitat Hanna J, Goldman-Wohl D, Hamani Y et al (2006) Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12(9):1065–1074CrossRef Hanna J, Goldman-Wohl D, Hamani Y et al (2006) Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12(9):1065–1074CrossRef
9.
Zurück zum Zitat Tabiasco J, Rabot M, Aguerre-Girr M et al (2006) Human decidual NK cells: unique phenotype and functional properties—a review. Placenta 27(Suppl A):S34–S39CrossRef Tabiasco J, Rabot M, Aguerre-Girr M et al (2006) Human decidual NK cells: unique phenotype and functional properties—a review. Placenta 27(Suppl A):S34–S39CrossRef
10.
Zurück zum Zitat Spits H, Artis D, Colonna M et al (2013) Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145–149CrossRef Spits H, Artis D, Colonna M et al (2013) Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145–149CrossRef
11.
Zurück zum Zitat Bonaccorsi I, Cantoni C, Carrega P et al (2010) The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production. PLoS One 5(11):e15080CrossRef Bonaccorsi I, Cantoni C, Carrega P et al (2010) The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production. PLoS One 5(11):e15080CrossRef
12.
Zurück zum Zitat Fuchs A, Cella M, Kondo T, Colonna M (2005) Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 106(6):2076–2082CrossRef Fuchs A, Cella M, Kondo T, Colonna M (2005) Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 106(6):2076–2082CrossRef
13.
Zurück zum Zitat Shemesh A, Brusilovsky M, Hadad U et al (2016) Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget 7(22):32933–32945CrossRef Shemesh A, Brusilovsky M, Hadad U et al (2016) Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget 7(22):32933–32945CrossRef
14.
Zurück zum Zitat Platonova S, Cherfils-Vicini J, Damotte D et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422CrossRef Platonova S, Cherfils-Vicini J, Damotte D et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422CrossRef
15.
Zurück zum Zitat Gur C, Porgador A, Elboim M et al (2010) The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 11(2):121–128CrossRef Gur C, Porgador A, Elboim M et al (2010) The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 11(2):121–128CrossRef
16.
Zurück zum Zitat Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27(45):5932–5943CrossRef Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27(45):5932–5943CrossRef
17.
Zurück zum Zitat Biassoni R, Cantoni C, Pende D et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181(1):203–214CrossRef Biassoni R, Cantoni C, Pende D et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181(1):203–214CrossRef
18.
Zurück zum Zitat Mandelboim O, Porgador A (2001) NKp46. Int J Biochem Cell Biol 33(12):1147–1150CrossRef Mandelboim O, Porgador A (2001) NKp46. Int J Biochem Cell Biol 33(12):1147–1150CrossRef
19.
Zurück zum Zitat Foster CE, Colonna M, Sun PD (2003) Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors. J Biol Chem 278(46):46081–46086CrossRef Foster CE, Colonna M, Sun PD (2003) Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors. J Biol Chem 278(46):46081–46086CrossRef
20.
Zurück zum Zitat Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD (2011) Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA 108(15):6223–6228CrossRef Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD (2011) Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA 108(15):6223–6228CrossRef
21.
Zurück zum Zitat Cantoni C, Ponassi M, Biassoni R et al (2003) The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure 11(6):725–734CrossRef Cantoni C, Ponassi M, Biassoni R et al (2003) The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure 11(6):725–734CrossRef
22.
Zurück zum Zitat Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL (2004) NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 172(2):899–906CrossRef Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL (2004) NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 172(2):899–906CrossRef
23.
Zurück zum Zitat Hollyoake M, Campbell RD, Aguado B (2005) NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol Biol Evol 22(8):1661–1672CrossRef Hollyoake M, Campbell RD, Aguado B (2005) NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol Biol Evol 22(8):1661–1672CrossRef
24.
Zurück zum Zitat De Maria A, Ugolotti E, Rutjens E et al (2009) NKp44 expression, phylogenesis and function in non-human primate NK cells. Int Immunol 21(3):245–255CrossRef De Maria A, Ugolotti E, Rutjens E et al (2009) NKp44 expression, phylogenesis and function in non-human primate NK cells. Int Immunol 21(3):245–255CrossRef
25.
Zurück zum Zitat Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP (2013) No monkey business: why studying NK cells in non-human primates pays off. Front Immunol 4:32PubMedPubMedCentral Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP (2013) No monkey business: why studying NK cells in non-human primates pays off. Front Immunol 4:32PubMedPubMedCentral
26.
Zurück zum Zitat Delahaye NF, Rusakiewicz S, Martins I et al (2011) Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17(6):700–707CrossRef Delahaye NF, Rusakiewicz S, Martins I et al (2011) Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17(6):700–707CrossRef
27.
Zurück zum Zitat Prada N, Antoni G, Commo F et al (2013) Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2(3):e23472CrossRef Prada N, Antoni G, Commo F et al (2013) Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2(3):e23472CrossRef
28.
Zurück zum Zitat Mantovani S, Mele D, Oliviero B, Barbarini G, Varchetta S, Mondelli MU (2015) NKp30 isoforms in patients with chronic hepatitis C virus infection. Immunology 146(2):234–242CrossRef Mantovani S, Mele D, Oliviero B, Barbarini G, Varchetta S, Mondelli MU (2015) NKp30 isoforms in patients with chronic hepatitis C virus infection. Immunology 146(2):234–242CrossRef
29.
Zurück zum Zitat Messaoudene M, Fregni G, Enot D et al (2016) NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution. OncoImmunology 5(12):e1154251CrossRef Messaoudene M, Fregni G, Enot D et al (2016) NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution. OncoImmunology 5(12):e1154251CrossRef
30.
Zurück zum Zitat Sivori S, Parolini S, Marcenaro E et al (2000) Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol 107(2):220–225CrossRef Sivori S, Parolini S, Marcenaro E et al (2000) Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol 107(2):220–225CrossRef
31.
Zurück zum Zitat Semeraro M, Rusakiewicz S, Minard-Colin V et al (2015) Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 7(283):283ra55CrossRef Semeraro M, Rusakiewicz S, Minard-Colin V et al (2015) Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 7(283):283ra55CrossRef
32.
Zurück zum Zitat Fend L, Rusakiewicz S, Adam J et al (2017) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. OncoImmunology 6(1):e1163456CrossRef Fend L, Rusakiewicz S, Adam J et al (2017) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. OncoImmunology 6(1):e1163456CrossRef
33.
Zurück zum Zitat Rusakiewicz S, Perier A, Semeraro M et al (2017) NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. OncoImmunology 6(1):e1137418CrossRef Rusakiewicz S, Perier A, Semeraro M et al (2017) NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. OncoImmunology 6(1):e1137418CrossRef
34.
Zurück zum Zitat Siewiera J, Gouilly J, Hocine H et al (2015) Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nat Commun 6:10183CrossRef Siewiera J, Gouilly J, Hocine H et al (2015) Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nat Commun 6:10183CrossRef
35.
Zurück zum Zitat Shemesh A, Tirosh D, Sheiner E et al (2015) First trimester pregnancy loss and the expression of alternatively spliced NKp30 isoforms in maternal blood and placental tissue. Front Immunol 6:189CrossRef Shemesh A, Tirosh D, Sheiner E et al (2015) First trimester pregnancy loss and the expression of alternatively spliced NKp30 isoforms in maternal blood and placental tissue. Front Immunol 6:189CrossRef
36.
Zurück zum Zitat Levi I, Amsalem H, Nissan A et al (2015) Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6(15):13835–13843CrossRef Levi I, Amsalem H, Nissan A et al (2015) Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6(15):13835–13843CrossRef
37.
Zurück zum Zitat Shemesh A, Kugel A, Steiner N et al (2016) NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget 7(43):70912–70923CrossRef Shemesh A, Kugel A, Steiner N et al (2016) NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget 7(43):70912–70923CrossRef
38.
Zurück zum Zitat Rosental B, Brusilovsky M, Hadad U et al (2011) Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 187(11):5693–5702CrossRef Rosental B, Brusilovsky M, Hadad U et al (2011) Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 187(11):5693–5702CrossRef
39.
Zurück zum Zitat Horton NC, Mathew SO, Mathew PA (2013) Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PloS one 8(3):e59552CrossRef Horton NC, Mathew SO, Mathew PA (2013) Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PloS one 8(3):e59552CrossRef
40.
Zurück zum Zitat Horton NC, Mathew PA (2015) NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front Immunol 6:31CrossRef Horton NC, Mathew PA (2015) NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front Immunol 6:31CrossRef
41.
Zurück zum Zitat Garzetti GG, Ciavattini A, Goteri G et al (1994) Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol 55(1):111–114CrossRef Garzetti GG, Ciavattini A, Goteri G et al (1994) Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol 55(1):111–114CrossRef
42.
Zurück zum Zitat Rajagopalan S, Long EO (2013) Found: a cellular activating ligand for NKp44. Blood 122(17):2921–2922CrossRef Rajagopalan S, Long EO (2013) Found: a cellular activating ligand for NKp44. Blood 122(17):2921–2922CrossRef
43.
Zurück zum Zitat Holtan SG, Creedon DJ, Haluska P, Markovic SN (2009) Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 84(11):985–1000CrossRef Holtan SG, Creedon DJ, Haluska P, Markovic SN (2009) Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 84(11):985–1000CrossRef
44.
Zurück zum Zitat Shemer-Avni Y, Kundu K, Shemesh A et al (2017) Expression of NKp46 splice variants in nasal lavage following respiratory viral infection: domain 1-negative isoforms predominate and manifest higher activity. Front Immunol 8:161CrossRef Shemer-Avni Y, Kundu K, Shemesh A et al (2017) Expression of NKp46 splice variants in nasal lavage following respiratory viral infection: domain 1-negative isoforms predominate and manifest higher activity. Front Immunol 8:161CrossRef
45.
Zurück zum Zitat Hadad U, Thauland TJ, Martinez OM, Butte MJ, Porgador A, Krams SM (2015) NKp46 clusters at the immune synapse and regulates NK cell polarization. Front Immunol 6:495CrossRef Hadad U, Thauland TJ, Martinez OM, Butte MJ, Porgador A, Krams SM (2015) NKp46 clusters at the immune synapse and regulates NK cell polarization. Front Immunol 6:495CrossRef
46.
Zurück zum Zitat Arnon TI, Achdout H, Lieberman N et al (2004) The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 103(2):664–672CrossRef Arnon TI, Achdout H, Lieberman N et al (2004) The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 103(2):664–672CrossRef
47.
Zurück zum Zitat MacFarlane A, Campbell KS (2006) Signal transduction in natural killer cells. In: Compans R et al (eds) Immunobiology of natural killer cell receptors. Current topics in microbiology and immunology, vol 298. Springer, Berlin, pp 23–57.‏CrossRef MacFarlane A, Campbell KS (2006) Signal transduction in natural killer cells. In: Compans R et al (eds) Immunobiology of natural killer cell receptors. Current topics in microbiology and immunology, vol 298. Springer, Berlin, pp 23–57.‏CrossRef
48.
Zurück zum Zitat Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9(5):495–502CrossRef Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9(5):495–502CrossRef
49.
Zurück zum Zitat Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510CrossRef Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510CrossRef
50.
Zurück zum Zitat Campbell KS, Purdy AK (2011) Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132(3):315–325CrossRef Campbell KS, Purdy AK (2011) Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132(3):315–325CrossRef
51.
Zurück zum Zitat Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci USA 94(24):13140–13145CrossRef Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci USA 94(24):13140–13145CrossRef
52.
Zurück zum Zitat Bloushtain N, Qimron U, Bar-Ilan A et al (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173(4):2392–2401CrossRef Bloushtain N, Qimron U, Bar-Ilan A et al (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173(4):2392–2401CrossRef
53.
Zurück zum Zitat Schlecker E, Fiegler N, Arnold A et al (2014) Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 74(13):3429–3440CrossRef Schlecker E, Fiegler N, Arnold A et al (2014) Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 74(13):3429–3440CrossRef
54.
Zurück zum Zitat Mandelboim O, Lieberman N, Lev M et al (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409(6823):1055–1060CrossRef Mandelboim O, Lieberman N, Lev M et al (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409(6823):1055–1060CrossRef
55.
Zurück zum Zitat Arnon TI, Achdout H, Levi O et al (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6(5):515–523CrossRef Arnon TI, Achdout H, Levi O et al (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6(5):515–523CrossRef
Metadaten
Titel
Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints
verfasst von
Avishai Shemesh
Michael Brusilovsky
Kiran Kundu
Aner Ottolenghi
Kerry S. Campbell
Angel Porgador
Publikationsdatum
20.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2104-x

Weitere Artikel der Ausgabe 12/2018

Cancer Immunology, Immunotherapy 12/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.